107 related articles for article (PubMed ID: 15845683)
1. The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine.
Olkkola KT; Isohanni MH; Hamunen K; Neuvonen PJ
Anesth Analg; 2005 May; 100(5):1352-1356. PubMed ID: 15845683
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):168-72. PubMed ID: 16918719
[TBL] [Abstract][Full Text] [Related]
3. The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.
Jokinen MJ; Ahonen J; Neuvonen PJ; Olkkola KT
Anesth Analg; 2000 Nov; 91(5):1207-12. PubMed ID: 11049910
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.
Orlando R; Piccoli P; De Martin S; Padrini R; Floreani M; Palatini P
Clin Pharmacol Ther; 2004 Jan; 75(1):80-8. PubMed ID: 14749694
[TBL] [Abstract][Full Text] [Related]
5. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Wang JS; Backman JT; Wen X; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Nov; 85(5):201-5. PubMed ID: 10608481
[TBL] [Abstract][Full Text] [Related]
6. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine.
Isohanni MH; Neuvonen PJ; Palkama VJ; Olkkola KT
Eur J Clin Pharmacol; 1998 Sep; 54(7):561-5. PubMed ID: 9832299
[TBL] [Abstract][Full Text] [Related]
7. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
[TBL] [Abstract][Full Text] [Related]
8. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Pharmacol Toxicol; 1999 Mar; 84(3):143-6. PubMed ID: 10193676
[TBL] [Abstract][Full Text] [Related]
9. Effect of itraconazole on the pharmacokinetics of inhaled lidocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):120-3. PubMed ID: 15447735
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.
Arlander E; Ekström G; Alm C; Carrillo JA; Bielenstein M; Böttiger Y; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Nov; 64(5):484-91. PubMed ID: 9834040
[TBL] [Abstract][Full Text] [Related]
11. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
[TBL] [Abstract][Full Text] [Related]
12. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
Damkier P; Hansen LL; Brosen K
Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
[TBL] [Abstract][Full Text] [Related]
13. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
14. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
15. The effect of erythromycin on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Raza A; Schneck DW
Eur J Clin Pharmacol; 2003 May; 59(1):51-6. PubMed ID: 12682802
[TBL] [Abstract][Full Text] [Related]
16. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
17. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
18. Effect of ciprofloxin on the pharmacokinetics of intravenous lidocaine.
Isohanni MH; Ahonen J; Neuvonen PJ; Olkkola KT
Eur J Anaesthesiol; 2005 Oct; 22(10):795-9. PubMed ID: 16211753
[TBL] [Abstract][Full Text] [Related]
19. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Aug; 64(2):177-82. PubMed ID: 9728898
[TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]